Cargando…
Comparison of the utility and applicability of the Sokal, Hasford, and EUTOS scores in a population of Chinese patients with chronic-phase chronic myeloid leukemia undergoing imatinib therapy
BACKGROUND: Tyrosine kinase inhibitors are increasingly used to treat chronic myeloid leukemia (CML), but loss of complete cytogenetic response (CCyR) indicates treatment failure. AIM: To compare the efficacy of Sokal, European Treatment Outcome Study (EUTOS), and Hasford prognostic scores with 3-mo...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4573067/ https://www.ncbi.nlm.nih.gov/pubmed/26392775 http://dx.doi.org/10.2147/OTT.S85313 |
_version_ | 1782390448970530816 |
---|---|
author | Xia, Leiming Qian, Wei Yang, Mingzhen Li, Qingsheng Liu, Fei Xie, Yanyan |
author_facet | Xia, Leiming Qian, Wei Yang, Mingzhen Li, Qingsheng Liu, Fei Xie, Yanyan |
author_sort | Xia, Leiming |
collection | PubMed |
description | BACKGROUND: Tyrosine kinase inhibitors are increasingly used to treat chronic myeloid leukemia (CML), but loss of complete cytogenetic response (CCyR) indicates treatment failure. AIM: To compare the efficacy of Sokal, European Treatment Outcome Study (EUTOS), and Hasford prognostic scores with 3-month and 12-month CCyR, event-free survival (EFS) and progression-free survival (PFS) in patients with chronic-phase CML (CP-CML) undergoing imatinib therapy. METHODS: We retrospectively analyzed the outcome of 210 patients with CP-CML treated at the First Affiliated Hospital of Anhui Medical University treated between January 2006 and December 2013. Sokal, EUTOS, and Hasford scores were compared with 3-month and 12-month CCyR, EFS, and PFS. RESULTS: Kaplan–Meier analyses revealed that 3-month and 12-month CCyR and PFS were lower in patients with high EUTOS scores, and intermediate or high Sokal and Hasford scores (all P<0.05). Furthermore, EFS was lower in patients with intermediate or high Sokal and Hasford scores (both P<0.05). Hasford score (hazard ratio =2.608, 95% confidence interval: 1.473–4.617, P=0.001) was independently associated with 3-month CCyR. CONCLUSION: Although all three scoring systems were associated with EFS, PFS, and 3-month and 12-month CCyR in the Kaplan–Meier analyses (except EFS with EUTOS), only the Hasford score was independently associated with 3m-CCyR, while EUTOS score and Sokal score were not independently associated with any of these outcomes. |
format | Online Article Text |
id | pubmed-4573067 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | Dove Medical Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-45730672015-09-21 Comparison of the utility and applicability of the Sokal, Hasford, and EUTOS scores in a population of Chinese patients with chronic-phase chronic myeloid leukemia undergoing imatinib therapy Xia, Leiming Qian, Wei Yang, Mingzhen Li, Qingsheng Liu, Fei Xie, Yanyan Onco Targets Ther Original Research BACKGROUND: Tyrosine kinase inhibitors are increasingly used to treat chronic myeloid leukemia (CML), but loss of complete cytogenetic response (CCyR) indicates treatment failure. AIM: To compare the efficacy of Sokal, European Treatment Outcome Study (EUTOS), and Hasford prognostic scores with 3-month and 12-month CCyR, event-free survival (EFS) and progression-free survival (PFS) in patients with chronic-phase CML (CP-CML) undergoing imatinib therapy. METHODS: We retrospectively analyzed the outcome of 210 patients with CP-CML treated at the First Affiliated Hospital of Anhui Medical University treated between January 2006 and December 2013. Sokal, EUTOS, and Hasford scores were compared with 3-month and 12-month CCyR, EFS, and PFS. RESULTS: Kaplan–Meier analyses revealed that 3-month and 12-month CCyR and PFS were lower in patients with high EUTOS scores, and intermediate or high Sokal and Hasford scores (all P<0.05). Furthermore, EFS was lower in patients with intermediate or high Sokal and Hasford scores (both P<0.05). Hasford score (hazard ratio =2.608, 95% confidence interval: 1.473–4.617, P=0.001) was independently associated with 3-month CCyR. CONCLUSION: Although all three scoring systems were associated with EFS, PFS, and 3-month and 12-month CCyR in the Kaplan–Meier analyses (except EFS with EUTOS), only the Hasford score was independently associated with 3m-CCyR, while EUTOS score and Sokal score were not independently associated with any of these outcomes. Dove Medical Press 2015-09-07 /pmc/articles/PMC4573067/ /pubmed/26392775 http://dx.doi.org/10.2147/OTT.S85313 Text en © 2015 Xia et al. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0) License The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. |
spellingShingle | Original Research Xia, Leiming Qian, Wei Yang, Mingzhen Li, Qingsheng Liu, Fei Xie, Yanyan Comparison of the utility and applicability of the Sokal, Hasford, and EUTOS scores in a population of Chinese patients with chronic-phase chronic myeloid leukemia undergoing imatinib therapy |
title | Comparison of the utility and applicability of the Sokal, Hasford, and EUTOS scores in a population of Chinese patients with chronic-phase chronic myeloid leukemia undergoing imatinib therapy |
title_full | Comparison of the utility and applicability of the Sokal, Hasford, and EUTOS scores in a population of Chinese patients with chronic-phase chronic myeloid leukemia undergoing imatinib therapy |
title_fullStr | Comparison of the utility and applicability of the Sokal, Hasford, and EUTOS scores in a population of Chinese patients with chronic-phase chronic myeloid leukemia undergoing imatinib therapy |
title_full_unstemmed | Comparison of the utility and applicability of the Sokal, Hasford, and EUTOS scores in a population of Chinese patients with chronic-phase chronic myeloid leukemia undergoing imatinib therapy |
title_short | Comparison of the utility and applicability of the Sokal, Hasford, and EUTOS scores in a population of Chinese patients with chronic-phase chronic myeloid leukemia undergoing imatinib therapy |
title_sort | comparison of the utility and applicability of the sokal, hasford, and eutos scores in a population of chinese patients with chronic-phase chronic myeloid leukemia undergoing imatinib therapy |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4573067/ https://www.ncbi.nlm.nih.gov/pubmed/26392775 http://dx.doi.org/10.2147/OTT.S85313 |
work_keys_str_mv | AT xialeiming comparisonoftheutilityandapplicabilityofthesokalhasfordandeutosscoresinapopulationofchinesepatientswithchronicphasechronicmyeloidleukemiaundergoingimatinibtherapy AT qianwei comparisonoftheutilityandapplicabilityofthesokalhasfordandeutosscoresinapopulationofchinesepatientswithchronicphasechronicmyeloidleukemiaundergoingimatinibtherapy AT yangmingzhen comparisonoftheutilityandapplicabilityofthesokalhasfordandeutosscoresinapopulationofchinesepatientswithchronicphasechronicmyeloidleukemiaundergoingimatinibtherapy AT liqingsheng comparisonoftheutilityandapplicabilityofthesokalhasfordandeutosscoresinapopulationofchinesepatientswithchronicphasechronicmyeloidleukemiaundergoingimatinibtherapy AT liufei comparisonoftheutilityandapplicabilityofthesokalhasfordandeutosscoresinapopulationofchinesepatientswithchronicphasechronicmyeloidleukemiaundergoingimatinibtherapy AT xieyanyan comparisonoftheutilityandapplicabilityofthesokalhasfordandeutosscoresinapopulationofchinesepatientswithchronicphasechronicmyeloidleukemiaundergoingimatinibtherapy |